Of note, a post-hoc analysis of the APRIL-SLE study demonstrated the usefulness of BLyS and APRIL serum levels as biomarkers to predict clinical response to atacicept (52), linked to a greater, dose-dependent pharmacodynamics effect. Here, TNFSF13 is linked to systemic lupus erythematosus.